A form of cell death that combines pyroptosis, apoptosis, and necroptosis may also help predict outcomes in colon cancer. This study turns that biological overlap into a two-cluster classification and a six-gene risk score. PANoptosis is a newly discovered cell death type, and it is tightly associated with immune system activities.

To date, the mechanism, regulation and application of PANoptosis in tumor is largely unknown. The aim is to explore the prognostic value of PANoptosis-related genes in colon adenocarcinoma, or COAD. In influenza A virus infection, a signaling pathway eventually results in cell death, and this cell death exhibits mixed features of apoptosis, necroptosis, and pyroptosis.

To describe this novel cell death modality, Thirumala-Devi Kanneganti and colleagues proposed the term PANoptosis in twenty nineteen. The key to PANoptosis is the assembly of the PANoptosome, which includes sensors, adaptors, and enzymatic effectors that transduce pathogenic signals to cell-death executioners.

Although PANoptosis patterns and related genes have been connected with survival and treatment response, research on PANoptosis and cancer is just in its infancy. The study used transcriptome sequencing and clinical data from The Cancer Genome Atlas-Colorectal Cancer repository.

The dataset included 458 unique patient cases, comprising 41 normal tissue samples and 483 COAD tissue samples, with quality control excluding incomplete records or ambiguous clinical outcomes. For the PANoptosis analysis, the study incorporated five distinct pathways from the Molecular Signatures Database, along with a set of immune-related genes.

The transcriptome data were analyzed using single-sample gene set enrichment analysis, or ssGSEA, to generate enrichment scores for PANoptosis-related and immune-related genes. This process used the GSVA package in R, and ssGSEA assesses gene set enrichment within individual samples to identify specific molecular signatures.

Survival analysis for PANoptosis genes was performed using the survival and survminer packages in R to identify genes associated with survival differences. The Cox proportional hazards model was applied for univariate survival analyses, investigating the relationship between gene expression levels and survival outcomes.

The analysis aimed to identify genes that were both differentially expressed in the immune-related groups and associated with survival, then calculated the intersection of differential genes and PANoptosis-related prognostic genes. Consensus clustering using the ConsensusClusterPlus package in R was applied to the intersected gene set, with a maximum of nine clusters tested.

For each cluster number, fifty resampling iterations were performed, and eighty percent of the samples were randomly selected in each iteration. Constructing a prognostic model is critical for patient stratification and treatment decision-making.

The Least Absolute Shrinkage and Selection Operator method was used to minimize overfitting during establishment of the prognostic model. Cox regression evaluated relationships between survival time and predictors, providing a robust and interpretable model for evaluating patients’ risk profiles.

Predictive accuracy of the risk score model was assessed using ROC curve and Calibration curve analyses. These methods offer quantitative measurement of the model’s performance and allow comparison with other clinical factors. Figure two connects PANoptosis activity with the immune landscape in colorectal cancer.

Panel A shows strong Spearman correlations for several immune features, including Treg at zero point seven nine, CCR at zero point eight zero, and parainflammation at zero point seven six. Panel B displays the four selected immune-feature scores across the two clusters, while panel C shows widespread differential expression, with genes marked as up, down, or not significant—supporting the authors’ use of immune-associated clustering for downstream analysis.

The study first performed comprehensive ssGSEA for the PANoptosis gene set and immune-related gene set, providing an integrated view of the PANoptosis and immune landscape in the COAD sample set. The enrichment scores of the PANoptosis gene set and four immune feature gene sets—Treg, parainflammation, CCR, and immune checkpoint—showed a strong correlation, with a Spearman correlation coefficient greater than zero point seven.

The strong correlation indicates likely co-regulation or mutual influence, although the precise mechanisms remain to be elucidated and warrant further investigation. After immune feature gene sets with a Spearman correlation coefficient greater than zero point seven were identified, hierarchical clustering was performed.

This categorized 189 samples into cluster one and 294 samples into cluster two. The scores for Treg, parainflammation, CCR, and checkpoint were significantly higher in cluster two, implying heightened immune response or activity in that cluster.

The clear separation into two clusters suggests inherent molecular differences between them. Figure three narrows the analysis to ten genes shared by the differentially expressed and PANoptosis-related prognostic sets, including PLCB2, CAVI, DAPK1, and GPX3.

Consensus clustering identifies two sample groups: Cluster A with one hundred eighty-one samples and Cluster B with two hundred seventy-seven. The survival curves then show statistically significant differences in overall survival, with p equals zero point zero one five, and progression-free survival, with p equals zero point zero zero eight, supporting these clusters as biologically and clinically distinct colorectal cancer subtypes.

Survival analysis was used to examine the prognostic implications of the identified clusters. The results indicate that cluster B may represent a biological subtype associated with lower disease progression risk and better survival outcomes.

Such a discovery could provide important insights for clinical decision-making and patient management. Figure four compares the mutation burden and immune context of clusters A and B. Panels A through C show mutation landscapes and a significant difference in tumor mutation burden, while panel D reports higher stromal, immune, and ESTIMATE scores for cluster A.

Panel E shows broadly increased immune-function and infiltration scores in cluster A, and panel F indicates a higher TIDE score there, suggesting greater potential for immune escape. In cluster A, the majority of the immune function scores were upregulated.

The Tumor Immune Dysfunction and Exclusion framework was employed to examine the potential for immune escape. Figure four F revealed a heightened TIDE score for cluster A, implying a pronounced potential for immune escape. Figure five shows single-cell maps from four datasets: GSE146771, EMTAB8107, GSE166555, and GSE179784.

The left panels label major cell populations, while the paired right panels display expression of a ten-gene signature, with color intensity indicating expression across cells. By examining the signature specifically in fibroblasts across independent datasets, the authors assess whether this cellular signal is reproducible and biologically localized, supporting its use in the later prognostic modeling.

Using the results from Lasso regression and Cox regression, a robust prognostic model was constructed. The pathway and deviation diagrams aided in selecting the optimal regularization strength, with the Lambda value determined to be ten. The risk score was constructed from the expression levels of six genes: MAPK12, ATP6V1C2, HOXC11, HOXD9, TRPM5, and EEF1A2, each multiplied by its listed coefficient.

Figure seven shows how the authors constructed a prognostic model from a ten-gene signature. Panels A and B display selection of the optimal lambda and the corresponding coefficient paths, while panels C and D arrange patients by increasing risk score and relate that score to survival outcomes.

Panel E is a heatmap showing genes with higher expression in the high-risk group, supporting the model’s use for separating COAD patients into groups with distinct survival patterns. ROC curve analysis was conducted for the training set, validation set, and entire sample set.

In the entire group, the one-year AUC was zero point seven three two, the three-year AUC was zero point seven zero seven, and the five-year AUC was zero point seven two nine. All AUC indicators surpassed the benchmark of zero point seven, indicating a satisfactory discriminatory capacity for the risk score.

The forest plots showed that the p-values for both univariate and multivariate Cox analyses were less than zero point zero zero one, signifying the robustness of the risk score as a predictor. Figure eight evaluates the risk score from several angles. ROC curves show overall AUC values of zero point seven three two at one year, zero point seven zero seven at three years, and zero point seven two nine at five years, while Cox analyses test its prognostic significance.

The concordance plot, nomogram, and calibration curve further assess model agreement and prediction reliability, supporting the risk score’s potential clinical usefulness in colorectal cancer prognosis. The analysis used data from 458 COAD cases, focused on five PANoptosis pathways from the Molecular Signatures Database and a comprehensive set of immune-related genes.

The approach identified distinct genetic COAD subtype clusters and developed a prognostic model based on these parameters. The study identified two genetic subtype clusters in COAD, marked by distinct profiles in PANoptosis pathways and immune-related gene expression.

A prognostic model incorporating these findings demonstrated significant predictive power for survival outcomes, underscoring the interplay between PANoptosis and immune responses in COAD. The study links PANoptosis-related gene patterns with immune activity and survival in colon adenocarcinoma, then builds a risk score with reported one-, three-, and five-year AUC values above zero point seven.

Clinical validation is still needed.